Shanghai Pharmaceuticals Holding (601607.SH): Saxagliptin/metformin extended-release tablets approved for production.

Shanghai Pharmaceuticals Holding (601607.SH) announced that its subsidiary Changzhou Pharmaceutical Factory Co., Ltd. (referred to as "Changzhou Pharmaceutical Factory") has received the Drug Registration Certificate (Certificate No: 2026S00307) issued by the National Medical Products Administration for its sustained-release metformin and saxagliptin tablets. The drug has been approved for production. The sustained-release metformin and saxagliptin tablets are suitable for adult type 2 diabetes patients who are undergoing combined treatment with saxagliptin and sustained-release metformin tablets. The drug was originally developed by Merck Sharp & Dohme and was first marketed in the United States in 2012. In June 2024, Changzhou Pharmaceutical Factory submitted an application for registration and approval to the National Medical Products Administration. As of the date of this announcement, the company has invested approximately 8.49 million yuan in research and development expenses for this drug.